loading...

US shares held back as Alzheimer drug test failure harms drug shares

NYSE traders

US shares open flat with pharmaceutical stocks down after drugs giant Eli Lilly said it would stop developing its Alzheimer drug following a trial failure.
Eil Lilly was down 14%, and rival Alzheimer drug developers Biogen and Axovant were down more than 5%.
Healthcare stocks, like other sectors, had been hitting record highs in the wake of the presidential election.
The Dow fell 4 to 19,019.49 points and the S&P 500 fell 6 to 2,196.71.
The Nasdaq lost 28 points to 5,358.12.
Reports that two patients had died in a trial of its leukaemia drug sent Juno Therapeutics down 33%.
Tractor giant John Deere though was an outstanding performer, rising 11% after its quarterly sales and earnings beat expectations.
Clothing maker Urban Outfitters dropped 8% after its sales undershot hopes.

Subscribe to receive free email updates:

0 Response to "US shares held back as Alzheimer drug test failure harms drug shares"

Posting Komentar